外媒：默克爾安保人員所住英國酒店出現疫情，但不影響參加G7峰會 sina.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.tw Daily Mail and Mail on Sunday newspapers.
Data from Merck’s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21
Saturday, May 22, 2021 12:20PM IST (6:50AM GMT)
New analyses from pivotal BAVENCIO
® study reinforce unique clinical benefits across different subgroups in the treatment of advanced urothelial carcinoma
New data from VISION study of TEPMETKO
® show association between liquid biopsy-identified biomarker and clinical response in
METex14 skipping NSCLC, supporting liquid biopsy as a means for monitoring treatment response
TEPMETKO
Oral presentations from independent studies reinforce the position of ERBITUX
® in 1L RAS wt mCRC and as backbone of treatment in SCCHN
Not intended for UK-, US- or Canada-based media
Data from Merck s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } });
COMUNICADO: Merck and BioMed X Institute Extend Collaboration to Continue Novel Research in Oncology and Autoimmunity - MERCK KGAA/PR NEWSWIRE
- Merck to support up to six additional research projects at the BioMed X Institute in Heidelberg within the next six years
- Call for application for a global crowdsourcing project, Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging
DARMSTADT, Germany, May 17, 2021 /PRNewswire/ Merck, a leading science and technology company, today announced the extension of its ongoing collaboration with BioMed X, Heidelberg, Germany. Under the new agreement, Merck will start up to six additional research projects at the BioMed X Institute, building on ongoing research projects in the fields of oncology (DNA damage response and RNA splic
Merck
Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic
Monday, April 26, 2021 9:37PM IST (4:07PM GMT)
Darmstadt, Germany:
New analysis indicates a specific immune repopulation pattern in people treated with MAVENCLAD, which may contribute to their ability to fight infections and develop protective antibodies from vaccines
Independent study from Israel showed MAVENCLAD-treated patients receiving COVID-19 vaccine were able to mount antibody response similar to that of healthy subjects
Updated safety data show MAVENCLAD-treated patients with confirmed or suspected COVID-19 continue to have a disease course similar to the general population
Not intended for UK and U.S. based media